Correct! And for other reasons that doesn't apply
Post# of 148344
(Total Views: 418)
Posted On: 08/21/2019 5:21:07 AM
Correct! And for other reasons that doesn't apply here.
AKAO didn't have a market. No one needs (expensive) antibiotics. There was no market for that in the first place. I think, I lost a few k on that.
SGYP had a better drug relatively (but no where close to CYDY) than AKAO, yet decided to market and sell globally, costing the if I remember about $150M/qrt in sales and marketing and operation in general. As soon as they made such a childish move, it was clear they were going broke. I think, I rode it from $4 to $7, and sold back last chunks in sub $4. It could have been somewhat an okay corp, if they had good mgmt. Noting that they change the management, to bring on board the most ridiculous and blind sighted people on board.
CYDY will be profitable instantaneously. More comparable with CPRX, and IONS, but with a much larger market.
Their book just after their 1st quarter of sales are going to shine. High revenue, and low operation cost. I'm expecting, something like $50 to $100M revenue. $35M operation, for their 1st quarter sales. Just as they launch, having maybe 2.5 months of sales alone.
AKAO didn't have a market. No one needs (expensive) antibiotics. There was no market for that in the first place. I think, I lost a few k on that.
SGYP had a better drug relatively (but no where close to CYDY) than AKAO, yet decided to market and sell globally, costing the if I remember about $150M/qrt in sales and marketing and operation in general. As soon as they made such a childish move, it was clear they were going broke. I think, I rode it from $4 to $7, and sold back last chunks in sub $4. It could have been somewhat an okay corp, if they had good mgmt. Noting that they change the management, to bring on board the most ridiculous and blind sighted people on board.
CYDY will be profitable instantaneously. More comparable with CPRX, and IONS, but with a much larger market.
Their book just after their 1st quarter of sales are going to shine. High revenue, and low operation cost. I'm expecting, something like $50 to $100M revenue. $35M operation, for their 1st quarter sales. Just as they launch, having maybe 2.5 months of sales alone.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼